Zipalertinib (CLN-081/TAS6417)

About Cullinan Therapeutics

Cullinan Therapeutics is a clinical-stage biopharma focused on translating deep immunology expertise into high-impact therapies for autoimmune diseases and cancer. The company employs a disciplined 'thriller or killer' portfolio strategy, yielding a focused pipeline of novel bispecific T cell engagers and kinase inhibitors. Recent milestones include completing a rolling NDA submission for zipalertinib in EGFR exon 20 NSCLC and reporting promising early clinical data for its bispecific candidates in hematology and autoimmune indications, positioning 2025 as a catalyst-rich year.

About Cullinan Therapeutics

Cullinan Therapeutics is a clinical-stage biopharma focused on translating deep immunology expertise into high-impact therapies for autoimmune diseases and cancer. The company employs a disciplined 'thriller or killer' portfolio strategy, yielding a focused pipeline of novel bispecific T cell engagers and kinase inhibitors. Recent milestones include completing a rolling NDA submission for zipalertinib in EGFR exon 20 NSCLC and reporting promising early clinical data for its bispecific candidates in hematology and autoimmune indications, positioning 2025 as a catalyst-rich year.

Therapeutic Areas